凝结芽孢杆菌活菌片治疗妊娠期便秘的临床观察

目的 观察和评价凝结芽孢杆菌活菌片(商品名:爽舒宝)治疗妊娠期便秘的临床疗效.方法 将80例妊娠期便秘患者随机分为治疗组和对照组,治疗组和对照组均为40例,两组均给予基础治疗.其中治疗组在基础治疗的同时加用凝结芽孢杆菌活菌片,首次2.1g,以后1.05g/次,3次/d,温水送服.观察治疗前后大便次数、粪便性状,有无排便不尽及排便费力感、腹部不适、腹胀、腹痛.结果 治疗组总有效率、大便频率明显高于对照组,差异有统计学意义(P＜0.05),同时治疗组患者治疗后无腹部不适、腹胀、排便费力、排便不尽感等新症状出现,明显优于对照组.结论 凝结芽孢杆菌活菌片辅助治疗妊娠期便秘疗效显著,值得临床推广.     

凝结芽孢杆菌活菌片预防剖腹产术后胃肠功能紊乱的临床观察

目的 观察和评价凝结芽孢杆菌活菌片(商品名:爽舒宝)预防剖腹产术后胃肠功能紊乱的临床疗效.方法 将60例妊娠期患者随机分为预防组和对照组,预防组和对照组均为30例.其中预防组住院后开始口服凝结芽孢杆菌活菌片,首次2.1g,以后1.05 g/次,3次/d,温水送服.观察两组患者剖腹产术后便秘、腹部不适、腹胀、腹痛、食欲不振等消化道症状.结果 预防组术后首次排便时间明显短于对照组,大便频率增加,腹部不适、腹胀、排便费力等伴随症状发生率明显低于对照组(P＜0.05).结论 凝结芽孢杆菌活菌片预防剖腹产术后胃肠功能紊乱疗效显著,值得临床推广.     

凝结芽孢杆菌活菌片预防产褥期便秘的临床观察

目的观察和评价凝结芽孢杆菌活菌片(商品名:爽舒宝)预防产褥期便秘的临床疗效。方法选取我院正常分娩(阴道分娩或剖宫产)的产妇200例,按随机数字表分为观察组和对照组,每组均为100例。观察组的100例产妇给予口服凝结芽孢杆菌活菌片,首次2.1 g,后1.05 g/次,3次/d,温水送服,疗程为14 d;对照组的100例产妇不服用任何微生态制剂药物。观察两组产妇便秘发生率和大便次数、大便量、大便性状等。结果观察组产妇便秘的发生率为15%,明显低于对照组的50%,差异有统计学意义(P<0.05);观察组产妇大便次数及大便量均明显多于对照组,大便性状明显比对照组有所改善,且无伴随症状。结论凝结芽孢杆菌活菌片预防产褥期便秘疗效显著,值得临床推广。     

小麦纤维素颗粒联合凝结芽孢杆菌活菌片治疗晚期妊娠便秘的临床观察CSCD

目的评估小麦纤维素颗粒联合凝结芽孢杆菌活菌片治疗晚期妊娠便秘的临床疗效及安全性。方法选择210例晚期妊娠便秘孕妇,采用随机数字表方法,将孕妇分为三组,分别为小麦纤维素组、益生菌组和联合组,每组70例。小麦纤维素组孕妇给予服用小麦纤维素颗粒(商品名:非比麸),3.5g/次,每天2次,连续服用2周。益生菌组孕妇给予口服凝结芽孢杆菌活菌片,首次2.1g,以后1.05g/次,3次/d,温水送服,连续服用2周。联合组孕妇给予口服凝结芽孢杆菌活菌片和小麦纤维素颗粒(用法同前),连续服用2周。比较三组孕妇治疗前后大便性状评分和每周排便次数,粪便菌群中乳杆菌属、肠球菌属、酵母样真菌变化情况。观察三组孕妇治疗过程中的不良反应。结果联合组孕妇总有效率为91.43%,明显高于益生菌组(84.29%)和小麦纤维素组(82.86%),差异均具有统计学意义(P<0.05)。治疗结束后,联合组孕妇大便性状评分和每周排便次数均优于小麦纤维素组和益生菌组,差异均具有统计学意义(P<0.05);联合组孕妇乳杆菌属和肠球菌属均高于小麦纤维素组和益生菌组,差异均具有统计学意义(P<0.05);联合组孕妇酵母样真菌均低于小麦纤维素组和益生菌组,差异均具有统计学意义(P<0.05)。三组孕妇治疗过程中未出现明显的恶心、呕吐、腹痛、腹泻、过敏等不良反应,治疗期间检测血糖无异常。结论麦纤维素颗粒联合凝结芽孢杆菌活菌片治疗晚期妊娠便秘具有良好的临床疗效,可有效改善孕妇的大便性状和增加排便次数,能有效改善肠道菌群分布,安全性较高,值得临床推广使用。     

小麦纤维素颗粒联合凝结芽孢杆菌活菌片 治疗晚期妊娠便秘的临床观察

摘要 目的 评估小麦纤维素颗粒联合凝结芽孢杆菌活菌片治疗晚期妊娠便秘的临床疗效及安全性。方法 选择210例晚期妊娠便秘孕妇,采用随机数字表方法,将孕妇分为三组,分别为小麦纤维素组、益生菌组和联合组,每组70例。小麦纤维素组孕妇给予服用小麦纤维素颗粒（商品名：非比麸）,3.5 g/次,每天2次,连续服用2周。益生菌组孕妇给予口服凝结芽孢杆菌活菌片,首次2.1 g,以后1.05 g/次,3次/d,温水送服,连续服用2周。联合组孕妇给予口服凝结芽孢杆菌活菌片和小麦纤维素颗粒（用法同前）,连续服用2周。比较三组孕妇治疗前后大便性状评分和每周排便次数,粪便菌群中乳杆菌属、肠球菌属、酵母样真菌变化情况。观察三组孕妇治疗过程中的不良反应。结果 联合组孕妇总有效率为91.43%,明显高于益生菌组（84.29%）和小麦纤维素组（82.86%）,差异均具有统计学意义（P<0.05）。治疗结束后,联合组孕妇大便性状评分和每周排便次数均优于小麦纤维素组和益生菌组,差异均具有统计学意义（P<0.05）;联合组孕妇乳杆菌属和肠球菌属均高于小麦纤维素组和益生菌组,差异均具有统计学意义（P<0.05）;联合组孕妇酵母样真菌均低于小麦纤维素组和益生菌组,差异均具有统计学意义（P<0.05）。三组孕妇治疗过程中未出现明显的恶心、呕吐、腹痛、腹泻、过敏等不良反应,治疗期间检测血糖无异常。结论 麦纤维素颗粒联合凝结芽孢杆菌活菌片治疗晚期妊娠便秘具有良好的临床疗效,可有效改善孕妇的大便性状和增加排便次数,能有效改善肠道菌群分布,安全性较高,值得临床推广使用。     

小麦纤维素颗粒联合凝结芽孢杆菌活菌片治疗晚期妊娠便秘的临床观察

目的评估小麦纤维素颗粒联合凝结芽孢杆菌活菌片治疗晚期妊娠便秘的临床疗效及安全性。方法选择210例晚期妊娠便秘孕妇,采用随机数字表方法,将孕妇分为三组,分别为小麦纤维素组、益生菌组和联合组,每组70例。小麦纤维素组孕妇给予服用小麦纤维素颗粒(商品名:非比麸),3.5g/次,每天2次,连续服用2周。益生菌组孕妇给予口服凝结芽孢杆菌活菌片,首次2.1g,以后1.05g/次,3次/d,温水送服,连续服用2周。联合组孕妇给予口服凝结芽孢杆菌活菌片和小麦纤维素颗粒(用法同前),连续服用2周。比较三组孕妇治疗前后大便性状评分和每周排便次数,粪便菌群中乳杆菌属、肠球菌属、酵母样真菌变化情况。观察三组孕妇治疗过程中的不良反应。结果联合组孕妇总有效率为91.43%,明显高于益生菌组(84.29%)和小麦纤维素组(82.86%),差异均具有统计学意义(P0.05)。治疗结束后,联合组孕妇大便性状评分和每周排便次数均优于小麦纤维素组和益生菌组,差异均具有统计学意义(P0.05);联合组孕妇乳杆菌属和肠球菌属均高于小麦纤维素组和益生菌组,差异均具有统计学意义(P0.05);联合组孕妇酵母样真菌均低于小麦纤维素组和益生菌组,差异均具有统计学意义(P0.05)。三组孕妇治疗过程中未出现明显的恶心、呕吐、腹痛、腹泻、过敏等不良反应,治疗期间检测血糖无异常。结论麦纤维素颗粒联合凝结芽孢杆菌活菌片治疗晚期妊娠便秘具有良好的临床疗效,可有效改善孕妇的大便性状和增加排便次数,能有效改善肠道菌群分布,安全性较高,值得临床推广使用。     

凝结芽孢杆菌活菌片联合热毒宁注射液治疗手足口病的疗效观察

【摘 要】 目的 观察和评价凝结芽孢杆菌活菌片（商品名：爽舒宝）联合热毒宁注射液治疗手足口病的临床疗效。方法 将81例手足口病患儿随机分为治疗组和对照组,治疗组41例,对照组40例,两组均给予中成药热毒宁注射液对症综合治疗。其中治疗组在治疗的同时加用凝结芽孢杆菌活菌片,1周岁以下,0.70 g/次,1周岁以上,1.05 g/次,3次/d,温水送服,疗程为7 d或治愈为止。对两组患儿疱疹、食欲、体温变化情况及食欲不振等并发症进行统计分析。结果 治疗组起效快,疱疹和腹泻消失时间、食欲和体温恢复正常时间显著短于对照组,且痊愈率、总有效率均高于对照组,差异具有统计学意义（P＜0.05或0.01）。结论 凝结芽孢杆菌活菌片联合热毒宁注射液治疗手足口病疗效显著,具有积极的临床意义。     

凝结芽孢杆菌活菌片预防先兆流产保胎妇女胃肠功能紊乱的临床观察

目的观察凝结芽孢杆菌活菌片（商品名：爽舒宝）预防先兆流产保胎妇女胃肠功能紊乱的临床疗效。方法将60例先兆流产保胎妇女随机分为爽舒宝预防组和对照组,预防组30例,对照组30例,两组均给予常规服用保胎药物,出现顽固性便秘后用开塞露通便,其中预防组在此基础上同时口服凝结芽孢杆菌活菌片首次2. 1 g,以后1.05 g/次,3次/d,温水送服,疗程2-4周。观察保胎期间孕妇胃肠功能紊乱情况和使用开塞露的通便次数。结果预防组患者胃肠功能紊乱的发生率显著低于对照组,差异有统计学意义（P〈0.05 ）。结论凝结芽孢杆菌活菌片预防先兆流产保胎妇女胃肠功能紊乱疗效显著,值得临床推广。     

凝结芽孢杆菌活菌片联合甲硝唑栓治疗细菌性阴道病的临床观察

目的观察凝结芽孢杆菌活菌片(商品名:爽舒宝)联合甲硝唑栓治疗细菌性阴道病的临床疗效。方法选取细菌性阴道病患者108例随机分为观察组和对照组,每组54例。两组患者均以甲硝唑栓放入阴道治疗,观察组在此基础上,口服凝结芽孢杆菌活菌片,首次6片,以后3片/次,3次/d,连用14d。观察两组患者用药后的临床疗效及不良反应,并比较治疗后随访半年内的复发率。结果观察组患者临床总有效率(90.7%)明显高于对照组(74.1%)(P0.05),治疗期间均未见明显的药物不良反应。治疗后随访半年,观察组的复发率(14.3%)明显低于对照组(32.5%)(P0.05)。结论凝结芽孢杆菌活菌片联合甲硝唑栓治疗细菌性阴道病疗效显著,能降低复发率,值得临床推广应用。     

口服凝结芽孢杆菌活菌片治疗外阴阴道假丝酵母菌病的疗效及预防复发作用

目的探讨口服凝结芽孢杆菌活菌片(商品名:爽舒宝)联合硝呋太尔制霉素阴道软胶囊治疗外阴阴道假丝酵母菌病的疗效及预防复发作用。方法选取外阴阴道假丝酵母菌病患者103例,随机分入观察组52例和对照组51例。两组患者均以硝呋太尔制霉素阴道软胶囊放入阴道,每晚1粒,连用7 d。观察组在此基础上,口服凝结芽孢杆菌活菌片,首次6片,以后3片/次,3次/d,连用14 d。观察两组患者治疗后的临床疗效及不良反应,并比较治疗后随访半年内的复发率。结果治疗后,观察组患者临床总有效率为88.5%,明显高于对照组的72.5%(χ2=4.16,P0.05),两组患者治疗中未发生明显的药物不良反应。治疗后随访半年,观察组的复发率(15.2%)明显低于对照组(37.8%)(χ2=5.55,P0.05)。结论口服凝结芽孢杆菌活菌片联合硝呋太尔制霉素阴道软胶囊用于外阴阴道假丝酵母菌病治疗中取得了较好的疗效,安全性好,并能降低其复发率,具有预防病情复发作用。     

A Unique Protease Cleavage Site Predicted in the Spike Protein of the Novel Pneumonia Coronavirus (2019-nCoV) Potentially Related to Viral Transmissibility

正Dear Editor,In December 2019, a novel human coronavirus caused an epidemic of severe pneumonia(Coronavirus Disease 2019,COVID-19) in Wuhan, Hubei, China(Wu et al. 2020; Zhu et al. 2020). So far, this virus has spread to all areas of China and even to other countries. The epidemic has caused 67,102 confirmed infections with 1526 fatal cases     

Curcuminoids as inhibitors of thioredoxin reductase: A receptor based pharmacophore study with distance mapping of the active site

Curcumin is the yellow pigment of turmeric that interacts irreversibly forming an adduct with thioredoxin reductase (TrxR), an enzyme responsible for redox control of cell and defence against oxidative stress. Docking at both the active sites of TrxR was performed to compare the potency of three naturally occurring curcuminoids, namely curcumin, demethoxy curcumin and bis-demethoxy curcumin. Results show that active sites of TrxR occur at the junction of E and F chains. Volume and area of both cavities is predicted. It has been concluded by distance mapping of the most active conformations that Se atom of catalytic residue SeCYS498, is at a distance of 3.56 from C13 of demethoxy curcumin at the E chain active site, whereas C13 carbon atom forms adduct with Se atom of SeCys 498. We report that at least one methoxy group in curcuminoids is necessary for interation with catalytic residues of thioredoxin. Pharmacophore of both active sites of the TrxR receptor for curcumin and demethoxy curcumin molecules has been drawn and proposed for design and synthesis of most probable potent antiproliferative synthetic drugs.     

Comparative morphology of the carpel in the Liliaceae: Hewardieae, Petrosavieae, and Tricyrteae

The young pistils in the melanthioid tribes, Hewardieae, Petrosavieae and Tricyrteae, are uniformly tricarpellate and syncarpous. They lack raphide idioblasts. All are multiovulate, with bitegmic ovules. The Petrosavieae are marked by the presence of septal glands and incomplete syncarpy. Tepals and stamens adhere to the ovary in the Hewardieae and the Petrosavieae but not in the Tricyrteae. Two vascular bundles occur in the stamens of the Hewartlieae and Tricyrtis latifolia. Ventral bundles in the upper part of the ovary of the Hewardieae are continuous with compound septal bundles and placental bundles in the lower part. Putative ventral bundles occur in the alternate position in the Tricyrteae and putative placental bundles in the opposite. position in the Petrosavieae. The dichtomously branched stigma in each carpel of the Tricyrteae is supplied by a bifurcated dorsal bundle.     

Enterovirus 71 3C proteolytically processes the histone H3 N-terminal tail during infection

Highlights
1. The N-terminal tail of histone H3 is specifically cleaved during EV71 infection.
2. Viral protease 3C is identified as a protease responsible for proteolytically processing the N-terminal H3 tail.
3. Our finding reveals a new epigenetic regulatory mechanism for Enterovirus 71 in virus-host interactions.     

Detection of EBV and HHV6 in the Brain Tissue of Patients with Rasmussen’s Encephalitis

Rasmussen’s encephalitis (RE) is a rare pediatric neurological disorder, and the exact etiology is not clear. Viral infection may be involved in the pathogenesis of RE, but conflicting results have reported. In this study, we evaluated the expression of both Epstein-Barr virus (EBV) and human herpes virus (HHV) 6 antigens in brain sections from 30 patients with RE and 16 control individuals by immunohistochemistry. In the RE group, EBV and HHV6 antigens were detected in 56.7% (17/30) and 50% (15/30) of individuals, respectively. In contrast, no detectable EBV and HHV6 antigen expression was found in brain tissues of the control group. The co-expression of EBV and HHV6 was detected in 20.0% (6/30) of individuals. In particular, a 4-year-old boy had a typical clinical course, including a medical history of viral encephalitis, intractable epilepsy, and hemispheric atrophy. The co-expression of EBV and HHV6 was detected in neurons and astrocytes in the brain tissue, accompanied by a high frequency of CD8⁺ T cells. Our results suggest that EBV and HHV6 infection and the activation of CD8⁺ T cells are involved in the pathogenesis of RE.     

Perinatal Vertical Transmission of Chikungunya Virus in Ruili,a Town on the Border between China and Myanmar

正Dear Editor,Chikungunya virus (CHIKV), an arbovirus in the family of Togaviridae, genus Alphavirus, is transmitted by the A.aegyptii or A. albopictus mosquito, and causes disease in humans characterized by fever, rash, and arthralgia (Silva and Dermody 2017; Suhrbier 2019). It was first reported in 1953 in Tanzania, and caused only a few outbreaks and sporadic cases in Africa and Asia in last century. However, in the epidemic in 2004, CHIKV acquired mutations that conferred enhanced transmission by the A. albopictus mosquito(Schuffenecker et al. 2006). Since then, it has successively caused outbreaks in Africa, the Indian Ocean, South East Asia, the South America, and Europe (Zeller et al. 2016).     

Development of a Novel Reverse Transcription Loop-Mediated Isothermal Amplification Method for Rapid Detection of SARS-CoV-2

In conclusion, the novel visual RT-LAMP assay is a simple, rapid, and sensitive approach for detection of SARS-CoV-2, and it is ready for application in primary care and community hospitals or health care centers, and even patients' own houses in response to the current SARS-CoV-2 epidemic because the assay does not require sophisticated equipment and skilled personnel. Furthermore, it is also ready to be used in fields for screening samples from wild animals and environments to facilitate the identification of potential intermediate hosts that mediate the cross-species transmission of SARS-CoV-2 from bats to humans.